Advexin (adenoviral p53)
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 81 (Table of Contents)
Published: 7 Mar-2007
DOI: 10.3833/pdr.v2007.i81.370 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
Introgen Therapeutics’ Advexin® therapy combines the wild type p53 tumour suppressor gene with a non-replicating, nonintegrating adenoviral gene delivery system...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS